ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
GeoVax Labs Inc

GeoVax Labs Inc (GOVX)

2.70
0.03
( 1.12% )
Updated: 13:19:54

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.70
Bid
2.70
Ask
2.73
Volume
2,302,883
2.65 Day's Range 3.288
1.0901 52 Week Range 10.2405
Market Cap
Previous Close
2.67
Open
2.90
Last Trade
16
@
2.69
Last Trade Time
13:21:21
Financial Volume
$ 6,630,561
VWAP
2.8792
Average Volume (3m)
3,302,742
Shares Outstanding
2,308,309
Dividend Yield
-
PE Ratio
-0.25
Earnings Per Share (EPS)
-11.25
Revenue
-
Net Profit
-25.97M

About GeoVax Labs Inc

Geovax Labs Inc is us-based clinical-stage biotechnology company. Geovax Labs Inc is us-based clinical-stage biotechnology company.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
GeoVax Labs Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker GOVX. The last closing price for GeoVax Labs was $2.67. Over the last year, GeoVax Labs shares have traded in a share price range of $ 1.0901 to $ 10.2405.

GeoVax Labs currently has 2,308,309 shares outstanding. The market capitalization of GeoVax Labs is $6.16 million. GeoVax Labs has a price to earnings ratio (PE ratio) of -0.25.

GOVX Latest News

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...

GeoVax to Present at the 36th Annual Roth Conference

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.4-12.90322580653.13.42.610579352.9439435CS
40.041.50375939852.664.91.8964899983.37872687CS
121.2282.43243243241.484.91.090133027422.9210855CS
26-1.545-36.39575971734.2454.91.090115453112.92559733CS
52-6.45-70.49180327879.1510.24051.09019246993.68862454CS
156-63.6-95.9276018166.3112.51.0901355751232.61005819CS
260-42.3-9445130.651.0901305179336.30160102CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
DCAPUnity Wealth Partners Dynamic Capital Appreciation & Options ETF
 20.10
(839.25%)
128.72k
RGCRegencell Bioscience Holdings Ltd
$ 26.10
(674.48%)
286.26k
SLRXSalarius Pharmaceuticals Inc
$ 4.61
(199.35%)
52.16M
GSUNGolden Sun Health Technology Group Ltd
$ 8.01
(56.14%)
272.47k
ATPCAgape ATP Corporation
$ 0.2189
(53.08%)
95.74M
FLYEFly E Group Inc
$ 1.64
(-74.29%)
11.58M
RNAZTransCode Therapeutics Inc
$ 0.2994
(-62.22%)
7.58M
JAGXJaguar Health Inc
$ 1.77
(-58.55%)
13.58M
MIRAMIRA Pharmaceuticals Inc
$ 2.6411
(-47.28%)
22.63M
SLNASelina Hospitality PLC
$ 0.0255
(-31.08%)
114.41M
ADILAdial Pharmaceuticals Inc
$ 1.3715
(29.39%)
153.62M
SPWRSunPower Corporation
$ 1.0401
(45.31%)
144.63M
SLNASelina Hospitality PLC
$ 0.0255
(-31.08%)
114.41M
NVDANVIDIA Corporation
$ 122.6201
(-0.74%)
109.22M
ATPCAgape ATP Corporation
$ 0.2189
(53.08%)
95.74M

GOVX Discussion

View Posts
glenn1919 glenn1919 4 hours ago
GOVX..................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783
👍️0
tw0122 tw0122 4 hours ago
The government will also provide around $343M for a clinical research organization to conduct the clinical trial. Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study

Currently, the FDA has approved two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.
👍️0
Monksdream Monksdream 2 days ago
GOVX under $3
👍️0
glenn1919 glenn1919 2 weeks ago
GOVX.......................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783
👍️0
Dantheoneman Dantheoneman 2 weeks ago
Looking Good!
👍️0
WARHAMMER WARHAMMER 3 weeks ago
Looks like a flagger
👍️0
Monksdream Monksdream 3 weeks ago
GOVX higher highs higher lows
I think that run was due in part to the pandemic rally in 20-21
Monkey pox cases have been on the increase lately but no where close to epidemic levels
You pays yore monies and you takes yore chances
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
pretty 5min
👍️0
PonkenPlonken PonkenPlonken 3 weeks ago
i think up
👍️0
WARHAMMER WARHAMMER 3 weeks ago
Monk, do you think GOVX has a chance at obtaining those previous highs in the $50 plus ranges if those funding numbers take place?
👍️0
glenn1919 glenn1919 4 weeks ago
GOVX................................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783
👍️0
Dantheoneman Dantheoneman 4 weeks ago
Let’s Go!!
👍️0
tw0122 tw0122 4 weeks ago
GOVXW .20 not mad alligator out at all.15
👍️0
Dantheoneman Dantheoneman 4 weeks ago
Nice Day!
👍️0
Anite Anite 4 weeks ago
FINTEL: The average one-year price target for GeoVax Labs (NasdaqCM:GOVX) has been revised to 77.78 / share. This is an increase of 1,170.83% from the prior estimate of 6.12 dated January 16, 2024.
The price target is an average of many targets provided by analysts. The latest targets range from a low of 5.05 to a high of 126.00 / share. The average price target represents an increase of 3,451.37% from the latest reported closing price of 2.19 / share.
👍️0
Invest-in-America Invest-in-America 4 weeks ago
"After a while, Crocodile!" (I think that was part of a Pre-Columbian SONG LYRIC, somewhere??)
👍️0
tw0122 tw0122 4 weeks ago
Warrants Selling .08s for .15 before the herd does ..catch you later crocodile lol
👍️0
Invest-in-America Invest-in-America 4 weeks ago
You too, Bro??
👍️0
TIMGZ TIMGZ 4 weeks ago
OFF TODAY!
👍️0
Invest-in-America Invest-in-America 4 weeks ago
GOVX (Warrants): THANKS for the heads-up!!! (Basically OFF today, but just now tossing a 'starter package' at the Warrants here, for my personal 'amusement'; and fret not, if I 'lose-my-shirt', I WON'T sissy-punk cry about it, Homeboy!!)
👍️0
tw0122 tw0122 4 weeks ago
$4s back and warrants are cheaper now .06
👍️0
Filterthenoise Filterthenoise 4 weeks ago
Go $GOVX
👍️0
TommyBoyTrader9460 TommyBoyTrader9460 4 weeks ago
$GOVX
$GOVX Strong mover today..with a test of the 200 day MA at $4.34 well within reach.. pic.twitter.com/wnnzoVjyBp— Chris from Massachusetts AKA TommyboyTrader (@autumnsdad1) June 24, 2024
👍️0
glenn1919 glenn1919 1 month ago
GOVX.....................https://stockcharts.com/h-sc/ui?s=GOVX&p=W&b=5&g=0&id=p86431144783
👍️0
Invest-in-America Invest-in-America 1 month ago
GOVXW: Hey, TW, aren't we both simply delighted that we grabbed $10K worth of these lovely WARRANTS on Monday of this week!!!! On-the-CHEAP!!!! And we both dumped it all about 1-hour ago, when our Warrants hit 2,225% GREEN!!!! Are we two GENIUS traders, or what, DUDE???!!!
👍️0
tw0122 tw0122 1 month ago
Why not ? look at that government funding $400million GOVX will be in $4s when they let it go
👍️0
Invest-in-America Invest-in-America 1 month ago
GOVXW( Warrants): Have now left our Galaxy!!!
👍️0
Filterthenoise Filterthenoise 1 month ago
$GOVX time!
👍️0
tw0122 tw0122 1 month ago
Uncle Sam $343 million and $45 million funding . Shorts running for the hills still. Shares of GeoVax (NASDAQ:GOVX) shot up 50% in mid-afternoon trading Tuesday amid news that the US government plans to fund a Phase 2b study of the company's next-generation COVID-19 vaccine.

Under the agreement, BARDA will award GeoVax up to $45M for the manufacturing of clinical materials and support for the Phase 2b study. The government will also provide around $343M for a clinical research organization to conduct the clinical trial.

Currently, the FDA has approved two mRNA COVID-19 vaccines, Pfizer (PFE) and BioNTech’s (BNTX) Comirnaty and Moderna’s (MRNA) Spikevax.




GEO-CM04S1 is currently being evaluated in three ongoing Phase 2 clinical trials:

As a primary vaccine in immunocompromised patients (with hematologic cancers receiving cell transplants or CAR-T therapy). ClinicalTrials.gov Identifier: NCT04977024. A recent presentation of unpublished data from the open-label portion of the trial indicates that GEO-CM04S1 is highly immunogenic in these patients, inducing both antibody responses, including neutralizing antibodies, and T cell responses.
As a booster vaccine in immunocompromised patients with chronic lymphocytic leukemia (CLL), a recognized high-risk group for whom current mRNA vaccines and monoclonal antibody (MAb) therapies appear inadequate relative to providing protective immunity. ClinicalTrials.gov Identifier: NCT05672355.
As a booster vaccine for healthy patients who have previously received the Pfizer or Moderna mRNA vaccine. This trial was fully enrolled in September 2023 and final results are expected in Fourth Quarter 2024, reflecting a 12-month tracking of study patients. ClinicalTrials.gov Identifier: NCT04639466.
About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel therapies and vaccines for solid tumor cancers and many of the world’s most threatening infectious diseases. The company’s lead program in oncology is a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax’s lead infectious disease candidate is GEO-CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations. Currently in three Phase 2 clinical trials, GEO-CM04S1 is being evaluated as a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized Covid-19 vaccines are insufficient, and as a booster vaccine in patients with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is in a Phase 2 clinical trial evaluating the vaccine as a more robust, durable Covid-19 booster among healthy patients who previously received the mRNA vaccines. GeoVax has a leadership team who have driven significant value creation across multiple life science companies over the past several decades. For more information, visit our website: www.geovax.com.
👍️0
it_happens it_happens 1 month ago
Wish I knew but I like the ride up.
👍️0
Awl416 Awl416 1 month ago
What leaked?
👍️0
Monksdream Monksdream 3 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 3 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 4 months ago
GOVX new 52 week lo
👍️0
Muhbruh Muhbruh 5 months ago
$GOVX bottom bio recent r/s 2.48M float with $3.54 cash per share and warrants at $6.21 CEO and CFO bought at these levels this month + 13G of 9.99% from 14/02/24

''GeoVax to Present at the 2024 BIO CEO & Investor Conference at February 26, 2024, 4:15 pm ET'' pic.twitter.com/8sXy5x4gpa— STOCKS Gambino (@StocksGambino) February 26, 2024
👍️0
Monksdream Monksdream 5 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 6 months ago
GOVX
🌈 1 🍆 1 👎️ 1 🤡 1 🩳 1
Monksdream Monksdream 6 months ago
GOVX new 52 week low
👍️0
Trompete Trompete 6 months ago
pure scam
👍️0
Monksdream Monksdream 6 months ago
GOVX new week low
👍️0
Renee Renee 6 months ago
GOVX: effective Jan. 31,2024 a one for 15 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
GetSeriousOK GetSeriousOK 6 months ago
they've been trying for weeks to pump up the price before the R/S, but it didn't fool anyone.

Interesting to see the SP here when the dust settles after the R/S.
👍️0
silkman silkman 6 months ago
Will average down when it hits .05 again
👍️0
Monksdream Monksdream 6 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 8 months ago
GOVX new 52 week low
👍️0
Monksdream Monksdream 9 months ago
GOVX new 52=week low
👍️0
Monksdream Monksdream 10 months ago
GOVX new 52 week low
👍️0
CarlCarlMcB CarlCarlMcB 11 months ago
Merry Christmas $$$$$$$$
👍️0
hinkydink hinkydink 11 months ago
Are you surprised?
This is a R/S dump stock.
The only ones that benefit from holding this stock are the crafty/lucky peeps or the insiders.
How long before the next R/S makes this stock look attractive to investors that don't know any better than to look past the hype?
👍️0
Monksdream Monksdream 11 months ago
GOVX new 52 week low
👍️0

Your Recent History

Delayed Upgrade Clock